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Abstract
We have previously demonstrated that chemically oversulfated fucoidan (OSF) but not native fucoidan (NF) effectively
suppresses the tube structure formation by human umbilical vein endothelial cells (HUVEC) on the basement membrane
preparation, Matrigel. In this study, using more defined systems where basic fibroblast growth factor (bFGF) induces the
tube formation by HUVEC on collagen gel, we investigated the mechanism responsible for the inhibition of angiogenesis by
OSF in vitro. Unlike NF and desulfated fucoidan (desF), OSF potently inhibited the bFGF-induced HUVEC migration and
tube formation. ELISA for tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in the
culture media indicated that OSF increased the bFGF-induced release of PAI-1 antigen, but not of t-PA antigen. Analyses of
the binding of bFGF to HUVEC surfaces and the following protein tyrosine phosphorylation revealed that OSF could
promote the cell binding and autophosphorylation of 140 and 160 kDa receptors. In heparitinase-treated HUVEC,
contrarily, the bFGF binding and PAI-1 release were decreased by OSF. These results suggest that OSF is a highly sulfated
unique polysaccharide that can promote the binding of bFGF to the heparan sulfate molecules required for binding to the
high affinity receptors with tyrosine kinase activity. The resultant increase in PAI-1 release may play a key role for the
prevention of cell migration accompanied by matrix proteolysis. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiogenesis is a fundamental process by which
microblood vessels are newly formed. Highly regu-
lated and transient angiogenesis plays an important
role in embryogenesis, wound healing and corpus
luteum formation [1,2]. By contrast, uncontrolled
and persistent angiogenesis is involved in cancer, di-
abetic retinopathy and rheumatoid [1,2]. Therefore,
suppression of the pathological neovascularization
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Abbreviations: NF, native fucoidan; OSF, oversulfated fucoidan; u-PA, urokinase-type plasminogen activator; HUVEC, human
umbilical vein endothelial cells ; PAI-1, plasminogen activator inhibitor-1; t-PA, tissue-type plasminogen activator; bFGF, basic ¢broblast
growth factor; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan; desF, desulfated fucoidan; DMEM, Dulbecco’s modi¢ed
Eagle’s medium; PBS, phosphate-bu¡ered saline; HPF, high power ¢eld
* Corresponding author. Fax: +81-92-863-0389; E-mail : shimeno@fukuoka-u.ac.jp
BBAMCR 14639 22-5-00
Biochimica et Biophysica Acta 1497 (2000) 127^134
www.elsevier.com/locate/bba
may result in new therapeutic approaches to these
disorders.
Fucoidan (NF) is a sulfated poly(L-fucopyranose)
present in brown marine algae and has been reported
previously to have anticoagulant activity in vitro and
in vivo [3]. Our previous studies have shown that the
anticoagulant activity of NF is improved by its fur-
ther sulfation, and that the oversulfated fucoidan
(OSF) is e¡ective for the prevention of lipopolysac-
charide-induced hepatic vein thrombosis in hyper-
lipemic rats [4]. OSF also inhibited the invasion of
3LL cells through the reconstituted basement mem-
brane, Matrigel, by suppressing the laminin-induced
urokinase-type plasminogen activator (u-PA) [5] and
the tube formation of cultured human umbilical vein
endothelial cells (HUVEC) in Matrigel by increasing
the release of plasminogen activator inhibitor-1
(PAI-1) [6]. These ¢ndings suggest that OSF acts as
a suppressor of cell migration that results from ma-
trix proteolysis.
In this study, we focus on how OSF increases the
release of PAI-1 from HUVEC cultured in Matrigel.
Because the reconstituted membrane, derived from
murine Engelbreth-Holm-Swarm sarcoma, contains
tissue-type plasminogen activator (t-PA), laminin,
type IV collagen and various angiogenic factors in-
cluding basic ¢broblast growth factor (bFGF), these
factors may cooperatively a¡ect the tube formation
by HUVEC. Therefore, the present experiments were
designed to test for the potential role of OSF in a
de¢ned angiogenic system, where bFGF induces the
tube formation by HUVEC on collagen gel. The re-
sults demonstrate that OSF increases the bFGF-in-
duced PAI-1 release from HUVEC by increasing
the binding of bFGF to the cell surface heparan sul-
fate (HS) molecules, which are required for binding
to the high a⁄nity receptors with tyrosine kinase
activity.
2. Materials and methods
2.1. Materials
The following materials were commercially ob-
tained: Fucus vesiculosus NF, porcine intestinal hep-
arin and murine Engelbreth-Holm-Swarm sarcoma
heparan sulfate proteoglycan (HSPG) from Sigma;
recombinant human bFGF from Becton Dickinson
Labware, Bedford, MA, USA; human plasma ¢bro-
nectin from Boehringer Ingelheim; Flavobacterium
heparinum heparitinase I from Seikagaku Kogyo
Co., Tokyo, Japan; porcine type I and type IV col-
lagens from Nitta Gelatin Co., Osaka, Japan; and
human plasminogen from American Diagnostica,
Inc., Greenwich, CT, USA.
2.2. HUVEC culture
Cryo HUVEC and the culture medium EGM-2
were purchased from Sanko Junyaku Co., Ltd., To-
kyo, Japan. EGM-2 is composed of modi¢ed MCDB
131 medium and the supplements that contain fetal
bovine serum, epidermal growth factor, vascular en-
dothelial growth factor, bFGF, insulin-like growth
factor, heparin, ascorbic acid, hydrocortisone, am-
photericin B and gentamicin. The cells were grown
in heparin-removed EGM-2 at 37‡C in a humidi¢ed
5% CO2 atmosphere. Subcultures were obtained by
treating the HUVEC cultures with 0.05% trypsin/
0.53 mM EDTA (Gibco) at 37‡C for 5 min. HUVEC
in the 3rd to 4th passages were used for experiments.
The culture medium used for the experiments was
modi¢ed MCDB 131 supplemented with 4% TCM,
a proprietary formulation of vitamins and other mol-
ecules (does not contain bFGF) from CELOX Lab-
oratories, MN, USA (TCM/MCDB 131).
2.3. Tube formation by HUVEC
Four hundred Wl of a type I collagen solution (2.4
mg/ml) containing bFGF (20 ng/ml), ¢bronectin and
plasminogen (20 Wg/ml each) were placed into each
well of a 24-well culture plate at 4‡C and allowed to
polymerize by incubation at 37‡C. HUVEC (5U104
cells) were seeded on the collagen gel in 1 ml of
TCM/MCDB 131 supplemented with the above con-
centrations of bFGF, ¢bronectin, plasminogen and,
if indicated, the de¢nite concentrations of polysac-
charide. The cells were incubated at 37‡C for 24 h
in a humidi¢ed 5% CO2 atmosphere. Three di¡erent
phase-contrast microscopic ¢elds (U100) per well
were photographed, and the micrographic pictures
were put on a computer. The total length of tube
structures in each photograph was measured using
Adobe Photoshop software.
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2.4. Assay of HUVEC migration
Polycarbonate ¢lter Transwell inserts (24 well size)
with 8-Wm pores were used for this invasion assay.
Type IV collagen (50 Wl from a 250 Wg/ml dilution in
TCM/MCDB 131 supplemented with the above con-
centrations of bFGF, ¢bronectin and plasminogen)
was applied to the upper surface of each ¢lter and
dried at 25‡C. To the lower chamber were added 700
Wl of TCM/MCDB 131 supplemented with bFGF,
¢bronectin, plasminogen and, if indicated, polysac-
charide. HUVEC (5U104 cells/ml, 200 Wl) were
added to the upper chamber and incubated at 37‡C
for 48 h. HUVEC that remained on the upper side of
the ¢lter were removed with cotton swabs. Filters
were then ¢xed and stained with Giemsa’s reagent
(Merck). The stained cells were counted in three
¢elds under a U100 high power ¢eld (HPF).
2.5. Puri¢cation and modi¢cation of NF
NF (200 mg) was puri¢ed on a Sephadex G-100
column (2.5U36 cm) equilibrated with 0.5 M NaCl.
OSF with a molecular mass of 100^130 kDa was
prepared as described previously [4]. Brie£y, the pu-
ri¢ed NF was further sulfated in a mixture of di-
methylformamide and sulfur trioxide^trimethylamine
complex at 50‡C for 24 h. The product was recovered
by ethanol precipitation, followed by puri¢cation on
the Sephadex G-100 column. The yield of OSF was
69%; the sulfate content was estimated to be 52.4%
(for NF, 31.2%). Desulfated fucoidan (desF) was
prepared by treating NF with 10% (v/v) methanol
in dimethyl sulfoxide at 80‡C for 18 h [4].
2.6. Assay of t-PA and PAI-1 antigens
Antigen levels of t-PA and PAI-1 in the condi-
tioned media were determined with ELISA kits, Tint-
Elize t-PA and TintElize PAI-1 (Biopool AB, Umea“,
Sweden), respectively, according to the manufactur-
er’s instructions.
2.7. Assay of bFGF binding
HUVEC were seeded at a density of 5U103 cells/cm2
into each well of a 24-well culture plate in heparin-
removed EGM-2 and allowed to reach con£uency.
After removal of the conditioned media, the HUVEC
monolayers were rinsed twice with 1 ml of Dulbec-
co’s modi¢ed Eagle’s medium (DMEM). The rinsed
monolayers were treated at 37‡C for 24 h in 1 ml of
TCM/MCDB 131 with or without 0.02 units/ml
heparitinase I. After washing with DMEM, the
HUVEC monolayers were treated at 4‡C for 30 min
with 1 ml of DMEM containing 20 ng/ml bFGF,
followed by extraction with 1 ml of PBS containing
0.5% Triton X-100. The cell lysates were centrifuged
at 9000Ug for 10 min, and the supernatants were
subjected to bFGF antigen assay. The assay was
performed with ELISA kit (TiterZyme FGF basic
EIA, PerSeptive Diagnostics, Inc.) according to the
manufacturer’s instructions.
2.8. Detection of protein tyrosine phosphorylation
Con£uent cultures of HUVEC in 175-cm2 tissue
culture £asks were rinsed with DMEM and incu-
bated at 37‡C for 30 min in 20 ml of TCM/MCDB
131 containing bFGF (20 ng/ml). Each cell culture
was detached by treating with 10 ml of 0.05% tryp-
sin/0.53 mM EDTA, and pelleted by centrifugation.
The pellet was washed three times with 10 ml of cold
PBS, and centrifuged again. The washed cells
(5U106) were lysed at 4‡C for 30 min in 100 Wl of
PBS containing 2 mM EDTA/10% glycerol/1% Tri-
ton X-100. Insoluble materials were removed by cen-
trifugation at 10 000Ug for 20 min. The cell-free ly-
sates (10 Wg protein/Wl, 20 Wl each) were subjected
to 10% SDS^polyacrylamide gel electrophoresis [7].
The separated proteins were transferred to a nitro-
cellulose membrane. The following detection of
phosphorylated tyrosines was performed with the
biotin-enhanced 4G10 Western blot kit for anti-
phosphotyrosine (Upstate Biotechnology, Inc., NY,
USA), according to the manufacturer’s instructions.
2.9. Statistical analysis of data
All values are expressed as the mean þ S.D., and
the signi¢cant levels between groups were assessed by
Student’s t-test.
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3. Results
3.1. E¡ects of fucoidans on bFGF-induced cell
migration and tube formation by HUVEC
Because the migration of endothelial cells is an
important process during angiogenesis, we ¢rst ex-
amined the e¡ects of NF, desF and OSF on the
bFGF-induced migration of HUVEC in Transwell
chambers. As shown in Fig. 1, HUVEC e⁄ciently
migrated into the lower side of the ¢lter in the pres-
ence of 20 ng/ml bFGF (control, 59.0 þ 11.36 cells/
HPFU100). The migration of HUVEC were unaf-
fected by the addition of 1^100 Wg/ml desF. NF at
100 Wg/ml signi¢cantly decreased the HUVEC migra-
tion (49% of the control, P6 0.05). The addition of
10 Wg/ml OSF resulted in a 68% inhibition of the
control cell migration (P6 0.05), but increasing its
concentration to 100 Wg/ml did not increase the in-
hibitory e¡ect. Additionally, the migration of HU-
VEC was not observed in the absence of bFGF.
We next assessed their abilities to suppress the
bFGF-induced capillary-like network formation by
HUVEC. As shown in Fig. 2, desF had no e¡ect
on the tube formation at the concentrations of
V100 Wg/ml. NF at 100 Wg/ml inhibited the tube
formation by 27% (P6 0.01), while OSF at 10 Wg/ml
inhibited the tube formation by 31% (P6 0.001). In
the presence of 100 Wg/ml OSF, HUVEC failed to
form the capillary-like networks (Fig. 3B).
Fig. 1. Concentration-dependent e¡ects of fucoidans on the
bFGF-induced HUVEC migration through collagen-coated ¢l-
ter. Experimental procedures are as described in Section 2.
Symbols: a, NF; b, OSF; E, desF. Each bar represents the
mean þ S.D. (n = 3). *P6 0.05, compared to control.
Fig. 2. E¡ects of fucoidans on the bFGF-induced tube forma-
tion by HUVEC. Experimental procedures are as described in
Section 2. Each bar represents the mean þ S.D. (n = 3).
*P6 0.01; **P6 0.001, compared to control.
Fig. 3. Light micrographs (U200) of the bFGF-induced tube
formation by HUVEC. Panel A: Control HUVEC. Panel B:
OSF (100 Wg/ml)-treated HUVEC.
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3.2. E¡ects of fucoidans on bFGF-induced release of
t-PA and PAI-1 from HUVEC
HUVEC were seeded on the collagen gel as de-
scribed in Section 2 and cultured in the medium con-
taining bFGF (20 ng/ml), plasminogen and ¢bronec-
tin (20 Wg/ml each). The HUVEC released t-PA and
PAI-1 antigens into the media at the concentrations
of 2.1 þ 0.13 ng/ml and 174.2 þ 4.32 ng/ml, respec-
tively, as determined at 24 h (Fig. 4). The simulta-
neous presence of OSF in the medium caused an
increase in the release of PAI-1 in a concentration-
dependent manner from 1 to 100 Wg/ml (panel A).
The addition of 100 Wg/ml OSF resulted in a 1.7-fold
increase in the PAI-1 levels (304.5 þ 5.03 ng/ml,
P6 0.001), compared to the control. Neither desF
nor NF in£uenced the release of PAI-1 from HU-
VEC at the concentration range of 1^500 Wg/ml.
On the other hand, the release of t-PA antigen was
una¡ected by the addition of these three fucoidans
(panel B).
3.3. HSPG present on cell surface and extracellular
matrix is essential for the e¡ect of OSF to
increase bFGF-induced release of PAI-1 from
HUVEC
HSPG present at the cell surface is an accessory
molecule required for binding of bFGF to the high
a⁄nity receptors with tyrosine kinase activity [8,9].
We therefore investigated how fucoidans acted to the
binding of bFGF to HSPG and the following cell
signaling. As shown in Fig. 5A, the HUVEC mono-
layers treated at 4‡C for 30 min with a saturating
concentration (20 ng/ml) of bFGF bound the angio-
genic factor at 47.6 þ 2.41 pg/well. The simultaneous
presence of OSF (10 Wg/ml) signi¢cantly increased
the bFGF binding (77.4 þ 4.57 pg/well, P6 0.01),
but that of NF did not. Heparin (10 Wg/ml) also
increased the bFGF binding by 1.3-fold (61.7 þ 5.58
pg/well, P6 0.05) compared to the control. By con-
trast, the addition of soluble HSPG resulted in a
decrease in bound bFGF (35.2 þ 4.43 pg/well,Fig. 4. Concentration-dependent e¡ects of fucoidans on the
bFGF-induced release of PAI-1 (panel A) and t-PA (panel B)
antigens from HUVEC. Experimental procedures are as de-
scribed in Section 2. Symbols: a, NF; b, OSF; E, desF. Each
bar represents the mean þ S.D. (n = 3). *P6 0.01; **P6 0.001,
compared to control.
Fig. 5. E¡ects of fucoidans and other polysaccharides on the
binding of bFGF to cell surfaces of heparitinase-untreated
(panel A) and -treated (panel B) HUVEC. Experimental proce-
dures are as described in Section 2. Each bar represents the
mean þ S.D. (n = 3). *P6 0.05; **P6 0.01, compared to each
control.
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P6 0.05). Fig. 5B shows the e¡ects of these polysac-
charides on the binding of bFGF to HUVEC mono-
layers, whose HS have largely been removed by hep-
aritinase. The heparitinase treatment (0.02 units/ml
for 24 h) reduced the binding of bFGF to the cell
layers (41% of untreated control). Unlike the results
from intact HUVEC, these polysaccharides showed a
tendency to suppress the binding of bFGF to HS-
removed HUVEC monolayers. OSF and heparin (10
Wg/ml each) decreased the bFGF binding from
28.1 þ 1.40 pg/well to 20.4 þ 2.67 pg/well and
23.4 þ 2.30 pg/well, respectively. Soluble HSPG also
had an inhibitory e¡ect (18.6 þ 3.31 pg/well). These
results suggest that the HS molecule is an essential
co-factor for the interaction of bFGF with HUVEC
and that OSF especially promotes this interaction. In
the HS-removed HUVEC, contrarily, these polysac-
charides may act as inhibitors of the bFGF^HUVEC
interaction rather than that they replace HS mole-
cules as the co-factor for bFGF-dependent receptor
activation. To con¢rm this possibility, we determined
the e¡ects of these polysaccharides on the bFGF-in-
duced release of PAI-1 from heparitinase-treated
HUVEC. As shown in Fig. 6, the HS-removed HU-
VEC reduced the bFGF-induced PAI-1 release to a
level of 18% (32.1 þ 1.50 ng/ml) of the untreated con-
trol. The presence of OSF or soluble HSPG (10
Wg/ml each) caused a further decrease in the PAI-1
release (OSF, 20.7 þ 3.73 ng/ml; soluble HSPG,
16.4 þ 3.78 ng/ml). NF and heparin also had a
weak inhibitory e¡ect. Fig. 7 shows the e¡ect of
OSF on the bFGF-induced protein tyrosine phos-
phorylation in HUVEC. The result indicates that
the autophosphorylation of the receptors with molec-
ular masses of 140 and 160 kDa is enhanced in the
concomitant presence of 50 Wg/ml OSF.
4. Discussion
The present results show that OSF, di¡erent from
the nature of other polysaccharides tested, has the
ability to promote the binding of bFGF to HS
present on the HUVEC surfaces and extracellular
matrix (Fig. 5A) and the following receptor tyrosine
phosphorylation (Fig. 7). HS present on HSPG binds
bFGF with a dissociation constant of 1038 to 1039
M [10^12] and may confer a stable, receptor-compat-
ible conformational change upon bFGF [9]. The bio-
logical response of cells to bFGF is mediated
through the high a⁄nity (Kd = 2^20U10311 M) cell
surface receptors that possess intrinsic tyrosine ki-
nase activity [13]. Yayon et al. [9] have previously
demonstrated that Chinese hamster ovary cell mu-
tants expressing high a⁄nity bFGF receptors, but
lacking HSPG, do not bind bFGF unless heparin
or soluble HS is included in the binding medium,
suggesting a possible role of the added polysaccha-
rides as the counterpart for the cell surface HS that
promotes the binding of bFGF to the high a⁄nity
receptors. In their experiments, the ability of heparin
to restore high a⁄nity receptor binding was detected
at the concentrations as low as 10^40 ng/ml. In the
present study, we also examined the restoration of
bFGF binding to HS-removed HUVEC at polysac-
charide concentrations as high as 10 Wg/ml (Fig. 5B).
The concentration range of OSF can e¡ectively cause
Fig. 7. E¡ect of OSF on the bFGF-induced receptor tyrosine
phosphorylation in HUVEC. Experimental procedures are as
described in Section 2.
Fig. 6. E¡ects of fucoidans and other polysaccharides on the
bFGF-induced release of PAI-1 from heparitinase-treated HU-
VEC. Experimental procedures are as described in Section 2.
Each polysaccharide was added at the concentration of 10
Wg/ml. Each bar represents the mean þ S.D. (n = 3). *P6 0.05,
compared to heparitinase-treated control.
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an increase in the bFGF-induced PAI-1 release from
intact HUVEC (Fig. 4) and decreases in the HUVEC
migration (Fig. 1) and tube formation (Fig. 2). How-
ever, the high concentrations of heparin, OSF and
also soluble HSPG failed to increase the localization
of bFGF at the HS-removed HUVEC monolayers
(Fig. 5B) and the following PAI-1 release (Fig. 6),
indicating that they could not act as the counterpart
of the removed HS at the high concentrations. On
the other hand, OSF and heparin signi¢cantly in-
creased the bFGF binding to intact HUVEC surfaces
(Fig. 5A). The resultant increase in bFGF binding
seems to directly contribute to the augment of
bFGF cell signaling for PAI-1 release (Fig. 6).
From these results, the HS present on cell surface
and extracellular matrix may play an important
role in the OSF-induced promotion of bFGF binding
to the high a⁄nity receptors and PAI-1 release. A
central question raised by these observations is how
OSF promotes the localization of bFGF to the HS
molecules. We assume that OSF could ¢rst bind
bFGF and simply transfer it to HS with higher af-
¢nity. Heparitinase treatment of the HUVEC mono-
layer largely decreases HS molecules. The resultant
minority of HS molecules may fail to act as the ac-
ceptors of bFGF. On the other hand, the predomi-
nant OSF may leave bFGF in the bound form and
rather prevent its transfer to the acceptor molecule
HS, since OSF showed a tendency to suppress the
binding of bFGF to HS-removed HUVEC mono-
layers (Fig. 5B) and the PAI-1 release (Fig. 6). There
is evidence that OSF at 10 Wg/ml, but not NF, in-
hibits the binding of lipopolysaccharide to HSPG on
HUVEC surface [14]. Both the high degree of sulfa-
tion and the high molecular weight (100^130 kDa)
may largely contribute to the unique nature of OSF.
Basic FGF is a potent mitogen that stimulates
proliferation, migration, and di¡erentiation of cells
[15,16]. Another fundamental question raised by
our ¢ndings is why the OSF-induced augment of
bFGF cell signaling does not promote the angiogen-
esis (Fig. 2). In general, bFGF promotes endothelial
cell migration by increasing PA production [17]. PAs
such as t-PA and u-PA can convert pro-collagenase
to active collagenase through converting plasmino-
gen to plasmin. Plasmin itself is also active in degrad-
ing extracellular components such as ¢bronectin and
laminin. Our data suggest that the increase in PAI-1
release with OSF shifts the balance of activation and
inhibition of plasminogen to the inhibition and re-
sults in the suppression of cell migration following
collagenolysis. Another striking feature of OSF is
that it selectively stimulates bFGF-induced release
of PAI-1. It is at present unknown why OSF does
not stimulate the t-PA release through promotion of
the bFGF binding to receptor(s). One possibility is
that, although OSF promotes the binding of bFGF
to HS, it also a¡ects the binding of bFGF to the
receptor(s) in a mode di¡erent from that of this cy-
tokine alone.
The observed increase in PAI-1 release may be
involved as at least one of the mechanisms by which
OSF inhibits the bFGF-induced cell migration and
tube formation by HUVEC in collagen gel and also
in Matrigel [6], where type IV collagen, t-PA and
bFGF are abundantly included. The released PAI-1
is accumulated in the cell surface and extracellular
matrix [18], where it may suppress the matrix degra-
dation required for cell migration by limiting plasmin
generation. In fact, increasing PAI-1 release in-
creased the accumulation of PAI-1 on the HUVEC
monolayers (data not shown). We have a particular
interest in the intracellular signaling for increasing
the release of PAI-1 from HUVEC. We have previ-
ously demonstrated that exposure of cultured HU-
VEC to cell permeable ceramide analogs and sphin-
gomyelinase leads to the increase in PAI-1 release
[19]. This ¢nding suggests an involvement of the in-
tracellular ceramide signaling event in PAI-1 release.
Tumor necrosis factor-K also utilizes the ceramide
formed by activation of lysosomal acidic sphingo-
myelinase for the induction of PAI-1 release from
HUVEC [20]. Additionally, Fan et al. [21] have
shown that suramin, a polysulphonated naphthylur-
ea, blocks angiogenesis. A recent report by Gill and
Windebank [22] suggests that suramin induces cer-
amide accumulation within neurons and leads to
apoptotic cell death. Therefore, further studies will
be needed to determine whether OSF-induced apo-
ptosis is an additional mechanism for its anti-angio-
genic e¡ects.
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